Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 16 of 16 entries
View as:

Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2

Phase: N/A Priority: Normal
NCT ID: NCT00085839 Org: User:
Start: 02/29/04 End: 03/31/07 Due: 03/31/08

Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma

Phase: N/A Priority: Normal
NCT ID: NCT01032070 Org: User:
Start: 09/27/10 End: 11/26/12 Due: 11/26/13

Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00033241 Org: User:
Start: 07/23/01 End: 04/22/04 Due: 04/22/05

A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function

Phase: N/A Priority: Normal
NCT ID: NCT00139620 Org: User:
Start: 08/22/05 End: 06/25/07 Due: 06/25/08

Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00116896 Org: User:
Start: 06/30/03 End: 12/31/04 Due: 12/31/05

Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205

Phase: N/A Priority: Normal
NCT ID: NCT01247922 Org: User:
Start: 05/23/11 End: 09/13/12 Due: 09/13/13

Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT00294762 Org: User:
Start: 01/31/06 End: 03/31/09 Due: 03/31/10

A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00373425 Org: User:
Start: 09/30/06 End: 06/30/14 Due: 06/30/15

OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00036647 Org: User:
Start: 11/01/01 End: 01/30/04 Due: 01/30/05

A Study of OSI-7904L Versus 5-FU/LV as Treatment in Patients With Biliary Tract Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00088270 Org: User:
Start: 08/31/04 End: 08/31/05 Due: 08/31/06

A Study of OSI-7904L as Treatment in Patients With Head and Neck Cancer Who Have Failed First-Line Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00116909 Org: User:
Start: 08/31/04 End: 08/31/05 Due: 08/31/06

Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00072631 Org: User:
Start: 11/05/03 End: 03/14/07 Due: 03/14/08

A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens

Phase: N/A Priority: Normal
NCT ID: NCT00294736 Org: User:
Start: 11/30/05 End: 09/30/07 Due: 09/30/08

OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT00040183 Org: User:
Start: 11/29/01 End: 01/15/04 Due: 01/15/05

Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01010945 Org: User:
Start: 02/03/10 End: 01/25/12 Due: 01/25/13

Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00073502 Org: User:
Start: 10/31/03 End: 10/31/03 Due: 10/31/04